Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cytokinetics, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CYTK
Nasdaq
8731
https://cytokinetics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cytokinetics, Inc.
Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug
- May 14th, 2024 1:46 pm
Health Care Roundup: Market Talk
- May 13th, 2024 9:24 pm
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
- May 13th, 2024 1:33 pm
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
- May 13th, 2024 1:33 pm
Cytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical Trials
- May 10th, 2024 4:37 pm
Cytokinetics First Quarter 2024 Earnings: Misses Expectations
- May 10th, 2024 11:47 am
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript
- May 9th, 2024 2:46 pm
Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...
- May 9th, 2024 11:01 am
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
- May 8th, 2024 9:10 pm
Cytokinetics Reports First Quarter 2024 Financial Results
- May 8th, 2024 8:00 pm
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- May 8th, 2024 11:30 am
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
- May 8th, 2024 11:30 am
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Development Fady Malik Sells Shares
- May 8th, 2024 6:23 am
Cytokinetics to Hold Annual Meeting of Stockholders
- May 7th, 2024 8:00 pm
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 2nd, 2024 8:00 pm
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- May 1st, 2024 2:01 pm
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
- Apr 29th, 2024 8:00 pm
Cytokinetics to Announce First Quarter Results on May 8, 2024
- Apr 24th, 2024 8:00 pm
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
- Apr 10th, 2024 1:27 pm
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
- Apr 10th, 2024 11:30 am
Scroll